# Bellini (NCT02755597)

> A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02755597
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AbbVie
- Conditions: Relapsed/Refractory Multiple Myeloma
- Interventions: Venetoclax; Bortezomib; Dexamethasone; Placebo for venetoclax
- Enrollment: 291
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on Bellini so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=bellini-nct02755597